Sunscreen containing disodium-phenyl dibenzimidazole tetrasulfonate, troxerutin and disodium terephthalylidene dicamphor sulfonic acid

Abstract

A cosmetic preparation containing a) the triethanolamine salt of disodium phenyl dibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate), b) troxerutin, c) the disodium salt of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid).

Description

[0001] Description

[0002] SUNSCREEN CONTAINING DISODIUM PHENYLDIBENZIMIDAZOLE TETRASULFONATE, TROXERUTIN AND DISODIUM TEREPHTHALYLIDENE DICAMPHERSULFONIC ACID

[0003] The present invention relates to a cosmetic preparation containing the triethanolamine salt of disodium phenyldibenzimidazoletetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate), troxerutin and the disodium salt of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid).

[0004] The trend away from a refined pallor toward "healthy, athletically tanned skin" has been unbroken for years. To achieve this, people expose their skin to sunlight, as this triggers pigment formation in the form of melanin. However, the ultraviolet radiation from sunlight also has a damaging effect on the skin. In addition to acute damage (sunburn), long-term damage such as an increased risk of skin cancer occurs with excessive exposure to light in the UVB range (wavelength: 280-320 nm). Excessive exposure to UVB and UVA radiation (wavelength: 320-400 nm) also leads to a weakening of the elastic and collagen fibers of the connective tissue. This causes numerous phototoxic and photoallergic reactions and results in premature skin aging.

[0005] To protect the skin, a number of sunscreen filter substances have been developed that can be used in cosmetic preparations. These UVA and UVB filters are summarized in most industrialized countries in the form of positive lists, such as Annex 7 of the Cosmetics Regulation.

[0006] However, the large number of commercially available sunscreens should not obscure the fact that these state-of-the-art preparations have a number of disadvantages.

[0007] For many years, there has been a steadily growing demand for UV-A filter substances. This is due in no small part to numerous government regulations that require a balanced ratio of UV-A and UV-B protection in sunscreens. However, the number of UV-A filters available in cosmetics is very limited. Oil-soluble compounds such as butyl methoxydibenzoylmethane or diethylamino hydroxybenzoyl hexyl benzoate are primarily used.

[0008] To achieve particularly high UV protection, however, it is necessary to incorporate UV-A filters into the aqueous phase as well. For this purpose, around the turn of the millennium, the company Symrise developed the compound disodium phenyldibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) as a water-soluble UV-A filter. However, this substance has the disadvantage of fluorescing strongly in certain wavelength ranges. This effect was first observed in nightclub visitors who sparkled bluish under "black light." This fluorescence phenomenon initially made the UV filter unusable for further use in cosmetics, and a number of research projects were launched to resolve the problem. Symrise found an initial promising solution in the use of troxerutin. This solution was successfully patented under EP2185126.

[0009] Although the combination with troxerutin led to a significant attenuation of fluorescence, a weak residual fluorescence still remained, which further hampered the use of disodium phenyl dibenzimidazole tetrasulfonate in cosmetics.

[0010] It was therefore the object of the present invention to solve this problem of the prior art and to further reduce the fluorescence of disodium phenyldibenzimidazoletetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) in cosmetic preparations.

[0011] Surprisingly, the problem is solved by a cosmetic preparation containing a) the triethanolamine salt of disodium phenyldibenzimidazoletetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate), b) troxerutin, c) the disodium salt of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid).

[0012] Although the person skilled in the art is familiar with EP2185126, this document could not point the way to the present invention.

[0013] According to the invention, it is advantageous if the preparation according to the invention contains disodium phenyldibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) in a concentration of 0.1 to 10% by weight, based on the total weight of the preparation. A content of 0.1 to 5% by weight, based on the total weight of the preparation, is preferred according to the invention.

[0014] This compound is neutralized with triethanolamine during the preparation process.

[0015] Furthermore, it is advantageous according to the invention if the preparation contains troxerutin in a concentration of 0.05 to 5% by weight, based on the total weight of the preparation. A content of 0.1 to 2.5% by weight, based on the total weight of the preparation, is preferred according to the invention.

[0016] Furthermore, the advantageous embodiments of the present invention are characterized in that the preparation contains terephthalylidene dicamphorsulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) in a concentration of 0.1 to 10% by weight, based on the total weight of the preparation. A content of 0.1 to 4% by weight, based on the total weight of the preparation, is preferred according to the invention.

[0017] This sulfonic acid is neutralized with sodium hydroxide during the preparation process.

[0018] Furthermore, it is advantageous according to the invention if the weight ratio of disodium phenyldibenzimidazoletetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) to the triethanolamine salt of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) is from 3:1 to 1:10.

[0019] It is advantageous in the sense of the present invention to prepare the preparation according to the invention as follows:

[0020] First, terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) is added to the water phase. This is then neutralized with sodium hydroxide solution and added as the hot water phase to the hot fat phase if the final product is an emulsion.

[0021] Separately, in a second aqueous phase, the disodium phenyldibenzimidazole tetrasulfonate is neutralized with triethanolamine and then stirred into the homogenized emulsion.

[0022] If the product is an aqueous gel, the aqueous phase of the neutralized disodium phenyldibenzimidazole tetrasulfonate is incorporated into the neutralized aqueous phase of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid). In other words, two aqueous phases, each containing one of the sulfonic acids, are prepared, neutralized separately, and then combined to form an aqueous preparation.

[0023] Advantageous embodiments of the present invention are characterized in that the preparation is free from 2-ethylhexyl 2-cyano-3,3-diphenylacrylate (octocrylene), homomenthyl salicylate (homosalate), 4-methoxycinnamic acid (2-ethylhexyl) ester, 3-(4-methylbenzylidene) camphor, 2-hydroxy-4-methoxybenzophenone (oxybenzone), methyl anthralinate (INCI: Methyl Anthraliate) and sulisobenzone (INCI: Benzophenone-4).

[0024] Furthermore, it is advantageous according to the invention if the preparation according to the invention is free from polyethylene glycol, polyethylene glycol ethers and polyethylene glycol esters (so-called PEG derivatives), is free from polyacrylates, mineral oils and silicone oils and is free from parabens, methylisothiazolinone, chloromethylisothiazolinone and DMDM ​​hydantoin.

[0025] It is advantageous for the purposes of the present invention if the preparation according to the invention is in the form of an emulsion. Oil-in-water emulsions (O / W emulsions) are preferred according to the invention.

[0026] In such a case, the advantageous embodiments of the invention are characterized in that the preparation contains one or more O / W emulsifiers selected from the group of compounds: stearic acid, stearate salts, polyglyceryl-3 methylglycose distearate, sodium cetearyl sulfate, polyglyceryl-10 stearate, sodium stearoyl glutamate, and disodium cetearyl sulfosuccinate (INCI: Disodium Cetearyl Sulfosuccinate). These are typically used in a concentration of 0.1 to 7% by weight, based on the total weight of the preparation.

[0027] According to the invention, it is advantageous if the preparation contains one or more compounds selected from the group consisting of xanthan gum (INCI: Xanthan Gum), welan gum (INCI: Welan Gum), gelan gum (INCI: Gelan Gum), sclerotium gum (INCI: Scerotium Gum), cellulose, and / or cellulose derivatives. Examples of advantageous celluloses and cellulose derivatives include microcrystalline cellulose, ethyl cellulose, propyl cellulose, hydroxypropyl cellulose, methoxyethyl cellulose, methoxypropyl cellulose, and carboxymethyl cellulose.

[0028] Furthermore, it is particularly advantageous according to the invention if the preparation according to the invention contains ethylhexylglycerin and / or 4-hydroxyacetophenone. If the preparation according to the invention contains only ethylhexylglycerin and no 4-hydroxyacetophenone, the advantageous use concentration according to the invention is from 0.1 to 0.5% by weight, based on the total weight of the preparation.

[0029] If the preparation according to the invention contains only 4-hydroxyacetophenone and no ethylhexylglycerol, the advantageous use concentration according to the invention is from 0.1 to 0.6% by weight, based on the total weight of the preparation.

[0030] If the preparation according to the invention contains both ethylhexylglycerol and 4-hydroxyacetophenone, the advantageous use concentration according to the invention is from 0.1 to 0.5% by weight for ethylhexylglycerol and from 0.1 to 0.6% by weight for 4-hydroxyacetophenone, in each case based on the total weight of the preparation.

[0031] It is furthermore advantageous according to the invention if the preparation contains silica and / or glass spheres with a particle diameter of 5 to 120 pm.

[0032] In addition, the advantageous embodiments of the present invention are characterized in that the preparation contains 2-(4'-(diethylamino)-2'-hydroxybenzoyl)-benzoic acid hexyl ester, 2,4,6-tris-[anilino-(p-carbo-2'-ethyl-1'-hexyloxy)]-1,3,5-triazine (INCI: Ethylhexyl Triazone) and / or 2,4-bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INGI: Bis-Ethylhexyloxyphenol methoxyphenyl Triazine).

[0033] Furthermore, it is advantageous according to the invention if the preparation according to the invention contains 2,4,6-tribiphenyl-4-yl-1,3,5-triazine (INGI: Tris-Biphenyl Triazine). In such a case, it is preferred according to the invention to use 2,4,6-tribiphenyl-4-yl-1,3,5-triazine (INGI: Tris-Biphenyl Triazine) in a concentration of 0.1 to 9.5% by weight, based on the total weight of the preparation.

[0034] Advantageous embodiments of the present invention are further obtained by adding 2-ethoxyethyl-(2Z)-2-cyano-2-[3-(3-methoxypropylamino)cyclohex-2-en-1-ylidene]acetate (INGI: Methoxypropylamino Cyclohexylidene Ethoxyethylcyanoacetate) and / or the compound to the preparation.

[0035] Both compounds can be added to the composition in a concentration of 0.1 to 5% by weight, based on the total weight of the preparation.

[0036] A further advantageous embodiment of the present invention is characterized in that the preparation contains lauryl glycoside and / or decyl glycoside.

[0037] Last but not least, the advantageous embodiments of the present invention are characterized in that the preparation contains one or more compounds selected from the group of the compounds butylene glycol dicaprylate / dicaprate, phenethyl benzoate, dibutyl adipate; diisopropyl sebacate, di-C12-13 alkyl tartrate, butyloctyl salicylate, diethylhexyl syringylidene malonate, hydratenated castor oil dimerate, triheptanoin, C12-13 alkyl lactate, C16-17 alkyl benzoate, propylheptyl caprylate, caprylic / capric triglyceride, diethylhexyl 2,6-naphthalate, octyldodecanol.

[0038] In addition, the composition according to the invention can contain the usual cosmetic ingredients. For example, the preparation can contain additional UV filters. The use of glycerin and / or ethanol is also particularly advantageous according to the invention.

[0039] A glycerol content of at least 5% by weight, based on the total weight of the preparation, is preferred according to the invention.

[0040] Advantageous embodiments of the present invention are characterized in that the preparation contains one or more compounds selected from the group of alpha-lipoic acid, folic acid, phytoene, D-biotin, coenzyme Q10, alpha-glucosylrutin, carnitine, carnosine, natural and / or synthetic isoflavonoids, flavonoids, creatine, creatinine, taurine, ß-alanine, panthenol, magnolol, honokiol, tocopheryl acetate, dihydroxyacetone; 8-hexadecene-1,16-dicarboxylic acid, glyceryl glycose, (2-hydroxyethyl)urea, vitamin E or its derivatives, hyaluronic acid and / or its salts and / or licochalcone A. According to the invention, it is advantageous if the preparation contains one or more alkanediols from the group of compounds 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol, 1,2-decanediol, and 2-methyl-1,3-propanediol. According to the invention, the use of 1,2-hexanediol is preferred.

[0041] It is furthermore advantageous in the sense of the present invention if the preparation according to the invention contains one or more perfume substances selected from the group of the compounds limonene, citral, linalool, alpha-isomethyl ionone, geraniol, citronellol, 2-isobutyl-4-hydroxy-4-methyltetrahydropyran, 2-tert-pentylcyclohexyl acetate, 3-methyl-5-phenyl-1-pentanol, 7-acetyl-1,1,3,4,4,6-hexamethyltetralin, alpha-amyl cinnamaldehyde, alpha-methyl ionone, amyl cinnamaldehyde, butylphenyl methylpropional cinnamal, amyl salicylate, amyl cinnamyl alcohol, anise alcohol, benzoin, benzyl alcohol, benzyl benzoate, benzyl cinnamate, benzyl salicylate, bergamot oil, bitter orange oil, butylphenyl methylpropional, cardamom oil, cedrol, cinnamal, Cinnamyl Alcohol, Citronellyl Methyl Crotonate, Citron Oil, Coumarin, Diethyl Succinate, Ethyllinalool, Eugenol, Evernia Furfuracea Extract, Evernia Prunastri Extract, Farnesol, Guaiac Wood Oil, Hexyl Cinnamal, Hexyl Salicylate, Hydroxycitronellal, Lavender Oil, Lemon Oil, Linayl Acetate, Tangerine Oil, Menthyl PCA,Contains methylheptenone, nutmeg oil, rosemary oil, sweet orange oil, terpineol, tonka bean oil, triethyl citrate and / or vanillin.

[0042] According to the invention, the preparation according to the invention advantageously contains film formers. Film formers within the meaning of the present invention are substances of various compositions that are characterized by the following property: If a film former is dissolved in water or other suitable solvents and the solution is then applied to the skin, it forms a film after the solvent evaporates, which essentially serves to fix the light filters to the skin and thus increase the water resistance of the product.

[0043] It is particularly advantageous to use film formers from the group of polymers based on polyvinylpyrrolidone (PVP) Particularly preferred are copolymers of polyvinylpyrrolidone, for example PVP hexadecene copolymer and PVP eicosene copolymer, which are available from GAF Chemicals Cooperation under the trade names Antaron V216 and Antaron V220. According to the invention, the preparation according to the invention is used for protection against skin aging (in particular for protection against UV-induced skin aging), for daily care, and as a sunscreen.

[0044] Comparison experiment

[0045] The following formulations were prepared and their fluorescence properties were investigated: The fluorescence (color intensity at 365 nm) was determined as follows:

[0046] First, a latex finger cot was saturated with the preparation. Then, on a 14 cm 228 mg of the emulsion was applied to a large piece of VITRO-SKIN® and rubbed in with a saturated finger cot. For easier handling, the VITRO-Skin piece was secured to a conventional glass slide using double-sided adhesive tape. The emulsion was rubbed in first with circular movements, then in a transverse and longitudinal direction across the slide; the "rubbing-in time" was 30 seconds.

[0047] This results in an application amount of 2 mg / cm 2 The Vitro Skin sample is dried at room temperature for 20 minutes and then measured. A corresponding VITRO-SKIN® sample without the applied emulsion serves as a reference.

[0048] The measurement is performed in a darkened room. The Vitro-Skin slides are placed on a black surface. A standard DSLR or DSLM camera (here a Canon PowerShot SX540 HS) is mounted vertically and directly above the slides at a height of 30 cm. A UV lamp is mounted in the same way (here a VL-6.LM 365 / 312 2x6W UV lamp, 230V EU; set to 365 nm). The images are taken with the camera at ISO 400; F = 4.0; self-timer 25s.

[0049] The images are analyzed using a program that can separate them into color channels. Olympus Stream Basic was used in this case. Using a histogram, the color channels of the images can be separated into RGB colors. The analyzed area of ​​the images must be selected appropriately so that only the slide is displayed in the histogram. The fluorescence value is determined based on the blue value at an excitation wavelength of 365 nm.

[0050] Examples

[0051] The following examples are intended to illustrate the present invention without limiting it. Unless otherwise stated, all quantities, proportions, and percentages are based on the weight and the total amount or the total weight of the preparations.

[0052] (continued)

Claims

1. Cosmetic preparation containing a) the triethanolamine salt of disodium phenyldibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate), b) troxerutin, c) the disodium salt of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid).

2. Cosmetic preparation according to claim 1, characterized in that the preparation contains disodium phenyldibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) in a concentration of 0.1 to 10 wt%, based on the total weight of the preparation.

3. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation contains troxerutin in a concentration of 0.05 to 5 wt%, based on the total weight of the preparation.

4. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation contains terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) in a concentration of 0.1 to 10 wt%, based on the total weight of the preparation.

5. Cosmetic preparation according to one of the preceding claims, characterized in that the weight ratio of disodium phenyldibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) to the disodium salt of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) is from 3:1 to 1:

10.

6. A method for producing a cosmetic emulsion according to one of the preceding claims, characterized in that the terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) is added to the aqueous phase, this is neutralized by means of sodium hydroxide and added as a hot aqueous phase to the hot oil phase, and subsequently the separately produced aqueous phase, in which the disodium phenyldibenzimidazole tetrasulfonate has been neutralized with triethanolamine, is stirred into the homogenized emulsion.

7. A method for producing an aqueous cosmetic gel according to one of the preceding claims, characterized in that the terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) is neutralized in a first aqueous phase using sodium hydroxide and subsequently with a separately produced second aqueous phase, in which The disodium phenyldibenzimidazole tetrasulfonate was neutralized with triethanolamine and combined.

8. Cosmetic preparation or method according to any of the preceding claims, characterized in that the preparation is free of 2-ethylhexyl-2-cyano-3,3-diphenyl acrylate (octocrylene), homomenthyl salicylate (homosalate), 4-methoxycinnamic acid (2-ethylhexyl) ester, 3-(4-methylbenzylidene)camphor, 2-hydroxy-4-methoxybenzophenone (oxybenzone), methyl anthralinate (INCI: Methyl Anthralinate) and sulisobenzone (INCI: Benzophenone-4).

9. Cosmetic preparation or method according to any of the preceding claims, characterized in that the preparation is free of polyethylene glycol, polyethylene glycol ethers and polyethylene glycol esters (so-called PEG derivatives), is free of polyacrylates, mineral oils and silicone oils, and is free of parabens, methylisothiazolinone, chloromethylisothiazolinone and DMDM ​​hydantoin.

10. Cosmetic preparation or method according to any of the preceding claims, characterized in that the preparation comprises one or more O / W emulsifiers selected from the group consisting of stearic acid, stearate salts, polyglyceryl-3-methylglycosederate, sodium cetearyl sulfate, polyglyceryl-10 stearate, sodium stearoyl glutamate, disodium cetearyl sulfosuccinate (INCI: Disodium Cetearyl Sulfosuccinate).

11. Cosmetic preparation or method according to any of the preceding claims, characterized in that the preparation contains one or more compounds selected from the group consisting of xanthan gum (INCI: Xanthan Gum), welan gum (INCI: Welan Gum), gelan gum (INCI: Gelan Gum), sclerotium gum (INCI: Scerotium Gum), cellulose and / or cellulose derivatives.

12. Cosmetic preparation or method according to any of the preceding claims, characterized in that the preparation contains ethylhexylglycerin and / or 4-hydroxyacetophenone.

13. Cosmetic preparation or method according to any of the preceding claims, characterized in that the preparation contains silica and / or glass beads with a particle diameter of 5 to 120 pm.

14. Cosmetic preparation or method according to any of the preceding claims, characterized in that the preparation contains 2-(4'-(Diethylamino)-2'-hydroxybenzoyl)-benzoic acid hexyl ester, 2,4,6-Tris-[anilino-(p-carbo-2'-ethyl-1'-hexyloxy)]-1,3,5-triazine (INCI: Ethylhexyl Triazone) and / or 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Bis-Ethylhexyloxyphenol methoxyphenyl Triazine).

15. Cosmetic preparation or method according to any of the preceding claims, characterized in that it contains 2,4,6-Tribiphenyl-4-yl-1,3,5-triazine (INCI: Tris-Biphenyl Triazine).

16. Cosmetic preparation or method according to one of the preceding claims, characterized in that 2-ethoxyethyl-(2Z)-2-cyano-2-[3-(3- methoxypropylamino)cyclohex-2-en-1 -ylidene]acetate (INCI: Methoxypropylamino Cyclohexylidene Ethoxyethylcyanoacetate) and / or the compound is added to the preparation.

17. Cosmetic preparation or method according to any of the preceding claims, characterized in that the preparation contains lauryl glucoside and / or decyl glucoside.

18. Cosmetic preparation or method according to any one of the preceding claims, characterized in that the preparation contains one or more compounds selected from the group consisting of butylene glycol dicaprylate / dicaprate, phenethyl benzoate, dibutyl adipate, diisopropyl sebacate, di-C12-13 alkyl tartrates, butyloctyl salicylate, diethylhexyl syringylidene malonate, hydrogenated castor oil dimerate, triheptanoin, C12-13 alkyl lactate, C16-17 alkyl benzoate, propylheptyl caprylate, caprylic / capric triglyceride, diethylhexyl 2,6-naphthalate, and octyldodecanol.

Images